Interventions to Improve Outcomes After AKI (COPE-AKI)

May 2024 Council

Lead Division/Office


Point(s) of Contact

Ivonne Schulman, M.D.

Executive Summary

Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. There is limited evidence to inform recommendations for processes of care interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. Since 2021, NIDDK has funded the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium, composed of 3 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC), to develop and test a process of care intervention that aims to reduce rehospitalizations, morbidity, and patient reported outcomes compared with usual care in patients after hospitalization with Stage 2 and 3 AKI.

A 5-year extension of the COPE-AKI clinical trial is proposed to fully meet the enrollment targets, ensure appropriate representation of under-represented minorities, complete participant follow-up, and allow for resources for data analysis and dissemination of study findings. There is currently no standard of care for patients after hospitalization with AKI. Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors.